Your browser doesn't support javascript.
loading
Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis.
Colalillo, Amalia; Hachulla, Eric; Pellicano, Chiara; Smith, Vanessa; Bergmann, Christina; Riemekasten, Gabriela; Zanatta, Elisabetta; Henes, Jörg; Launay, David; Marcoccia, Antonella; Gheorghiu, Ana Maria; Truchetet, Marie-Elise; Iannone, Florenzo; Simeón Aznar, Carmen Pilar; Oliveira, Susana; Vonk, Madelon; Del Galdo, Francesco; Rosato, Edoardo.
Afiliação
  • Colalillo A; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Hachulla E; University of Lille, INSERM, CHU Lille, Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, CERAINOM, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Pellicano C; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Smith V; Department of Internal Medicine and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium.
  • Bergmann C; Department of Internal Medicine, University Hospital Erlangen, Erlangen, Germany.
  • Riemekasten G; Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany.
  • Zanatta E; Rheumatology Unit, Padova University Hospital, Padua, Italy.
  • Henes J; Center for Interdisciplinary Rheumatology, Auto-inflammatory Diseases and Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
  • Launay D; University of Lille, INSERM, CHU Lille, Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, CERAINOM, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, France.
  • Marcoccia A; Centro di Riferimento Interdisciplinare, Interdipartimentale per la Diagnosi Precoce della Sclerodermia (CRIIS), Sandro Pertini Hospital, Rome, Italy.
  • Gheorghiu AM; Carol Davila University on Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Hospital, Bucharest, Romania.
  • Truchetet ME; Department of Rheumatology, CHU de Bordeaux, Bordeaux, France.
  • Iannone F; Rheumatology Unit, University of Bari, Bari, Italy.
  • Simeón Aznar CP; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Oliveira S; Systemic Immunomediated Diseases Unit, Department of Medicine, Amadora, Portugal.
  • Vonk M; Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Del Galdo F; Leeds Raynaud's and Scleroderma Program, NIHR Biomedical Research Centre Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, England.
  • Rosato E; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. Electronic address: edoardo.rosato@uniroma1.it.
Chest ; 2024 Jun 06.
Article em En | MEDLINE | ID: mdl-38849072
ABSTRACT

BACKGROUND:

The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a "gray zone" of unclear clinical significance. RESEARCH QUESTION What is the diagnostic performance of the main parameters used for PH screening in detecting patients with systemic sclerosis (SSc) with an mPAP of 21 to 24 mm Hg at RHC? STUDY DESIGN AND

METHODS:

Patients with SSc from the European Scleroderma Trials and Research (EUSTAR) database with available tricuspid annular plane systolic excursion (TAPSE), systolic PAP (sPAP), and mPAP data were included. Patients with mPAP 21 to 24 mm Hg and patients with mPAP ≤ 20 mm Hg were considered for the analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated.

RESULTS:

TAPSE/sPAP was lower in the group of patients with SSc with mPAP 21 to 24 mm Hg than in the non-PH group (0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mm Hg, respectively; P < .01). No difference was found in other parameters between the two groups. Diffusing capacity of the lungs for carbon monoxide (Dlco) < 80% of the predicted value had the highest sensitivity (88.9%) and NPV (80%), but the lowest specificity (18.2%) and PPV (30.8%) in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity (78.9%), PPV (50%), and accuracy (68.1%); its NPV was 75.4%, and its sensitivity was 45.1%.

INTERPRETATION:

Dlco < 80% of the predicted value is the parameter with the highest sensitivity and NPV in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg has the highest specificity, PPV, and accuracy and, therefore, can be a useful additional parameter to decrease the number of unnecessary RHCs.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Chest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Chest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália